GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews underway in four markets including the US.
GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5, new data show
FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results
Experimental hepatitis B drug might offer ‘functional cure’ for a subset of patients | CNN
Ahead of ASCO, all eyes on pancreatic cancer
Experimental hepatitis B drug may offer 'functional cure' for some patients
Epatite B cronica, Gsk: "Con bepirovirsen tassi guarigione funzionale significativi"
Nova injeção elimina completamente hepatite B em 20% dos pacientes
Experimental hepatitis B drug might offer 'functional cure' for a subset of patients
GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five…
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for…
An experimental GSK drug helped 1 in 5 patients with chronic hepatitis B achieve what's known as a functional cure, vastly…
Drug could provide a cure for condition that affects more than 250mn people
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access…
Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues…
